NeXT Personal Dx - Personalis Powered to see MRD that previously avoided detection 1-6 NeXT Personal® Dx is a tumor-informed molecular residual disease (MRD) liquid biopsy with ultra-high sensitivity and sp
Careers in Precision Oncology - Personalis We’re looking for team members who are driven to advance the field of precision oncology Together, we can transform the future of cancer care
Personalis and Academic Partners to Present Latest Data on . . . FREMONT, Calif --(BUSINESS WIRE)--May 22, 2025-- Personalis, Inc (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois